Literature DB >> 23096450

Methylation status of TUSC3 is a prognostic factor in ovarian cancer.

Dietmar Pils1, Peter Horak, Petr Vanhara, Mariam Anees, Michaela Petz, Angela Alfanz, Alfred Gugerell, Michael Wittinger, Andreas Gleiss, Veronika Auner, Dan Tong, Robert Zeillinger, Elena-Ioana Braicu, Jalid Sehouli, Michael Krainer.   

Abstract

BACKGROUND: Current prognostic information in ovarian cancer is based on tumor stage, tumor grade, and postoperative tumor size. Reliable molecular prognostic markers are scarce. In this article, the authors describe epigenetic events in a frequently deleted region on chromosome 8p22 that influence the expression of tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene in ovarian cancer.
METHODS: Messenger RNA expression and promoter hypermethylation of TUSC3 were studied in ovarian cancer cell lines and in tumor samples from 2 large, independent ovarian cancer cohorts using polymerase chain reaction-based methods.
RESULTS: The results indicated that TUSC3 expression is decreased significantly because of promoter methylation in malignant ovarian tumors compared with benign controls. Almost 33% of ovarian cancer samples had detectable TUSC3 promoter methylation. Furthermore, methylation status of the TUSC3 promoter had a significant and independent influence on progression-free and overall survival.
CONCLUSIONS: TUSC3 hypermethylation predicted progression-free and overall survival in ovarian cancer. The current observations suggested a role for N-glycosylating events in ovarian cancer pathogenesis in general and identified the epigenetic silencing of TUSC3 as a prognostic factor in this disease.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096450     DOI: 10.1002/cncr.27850

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect.

Authors:  Juan Ravell; Benjamin Chaigne-Delalande; Michael Lenardo
Journal:  Curr Opin Pediatr       Date:  2014-12       Impact factor: 2.856

Review 2.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

Review 3.  TUSC3: functional duality of a cancer gene.

Authors:  Kateřina Vašíčková; Peter Horak; Petr Vaňhara
Journal:  Cell Mol Life Sci       Date:  2017-09-19       Impact factor: 9.261

4.  TUSC3 suppresses glioblastoma development by inhibiting Akt signaling.

Authors:  Zhenfeng Jiang; Mian Guo; Xiangtong Zhang; Lifen Yao; Jia Shen; Guizhen Ma; Li Liu; Liwei Zhao; Chuncheng Xie; Hongsheng Liang; Haiyang Wang; Minwei Zhu; Li Hu; Yuanyuan Song; Hong Shen; Zhiguo Lin
Journal:  Tumour Biol       Date:  2016-05-13

5.  Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.

Authors:  Kathleen Conway; Sharon N Edmiston; Chiu-Kit Tse; Christopher Bryant; Pei Fen Kuan; Brionna Y Hair; Eloise A Parrish; Ryan May; Theresa Swift-Scanlan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-25       Impact factor: 4.254

6.  Quantitative detection of TUSC3 promoter methylation -a potential biomarker for prognosis in lung cancer.

Authors:  Uta Duppel; Matthias Woenckhaus; Christian Schulz; Johannes Merk; Wolfgang Dietmaier
Journal:  Oncol Lett       Date:  2016-08-01       Impact factor: 2.967

7.  Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival.

Authors:  Haiyan Wang; Juanjuan Wen; Hai Wang; Qinq Guo; Shanshan Shi; Qunli Shi; Xiaojun Zhou; Qi Liu; Guangming Lu; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

8.  UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells.

Authors:  Kenzui Taniue; Tomoatsu Hayashi; Yuki Kamoshida; Akiko Kurimoto; Yasuko Takeda; Lumi Negishi; Kei Iwasaki; Yoshifumi Kawamura; Naoki Goshima; Tetsu Akiyama
Journal:  Oncogene       Date:  2019-10-03       Impact factor: 9.867

9.  Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Authors:  Arkadeep Sinha; David Cherba; Heather Bartlam; Elizabeth Lenkiewicz; Lisa Evers; Michael T Barrett; Brian B Haab
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

10.  Effects of RNAi-mediated TUSC3 silencing on radiation-induced autophagy and radiation sensitivity of human lung adenocarcinoma cell line A549 under hypoxic condition.

Authors:  Ya-Guang Li; Nai-Xin Liang; Ying-Zhi Qin; Dong-Jie Ma; Chang-Jin Huang; Lei Liu; Shan-Qing Li
Journal:  Tumour Biol       Date:  2016-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.